Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Rating of “Moderate Buy” by Analysts

by · The Markets Daily

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) have been assigned an average rating of “Moderate Buy” from the six research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $39.00.

Several analysts recently commented on ARTV shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Needham & Company LLC reiterated a “buy” rating and issued a $41.00 price objective on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Finally, Wall Street Zen raised shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th.

Get Our Latest Stock Report on ARTV

Insider Activity

In related news, CEO Fred Aslan sold 23,429 shares of Artiva Biotherapeutics stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $10.92, for a total value of $255,844.68. Following the completion of the transaction, the chief executive officer owned 1,449,765 shares in the company, valued at approximately $15,831,433.80. This trade represents a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Subhashis Banerjee sold 8,222 shares of the business’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $12.01, for a total transaction of $98,746.22. Following the transaction, the insider owned 142,047 shares in the company, valued at $1,705,984.47. This trade represents a 5.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have purchased 406,203 shares of company stock worth $3,937,983 and have sold 32,080 shares worth $359,739. Company insiders own 1.80% of the company’s stock.

Hedge Funds Weigh In On Artiva Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. 5AM Venture Management LLC bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter valued at about $22,827,049. Blue Owl Capital Holdings LP purchased a new stake in Artiva Biotherapeutics during the second quarter valued at approximately $8,483,000. BlackRock Inc. acquired a new stake in Artiva Biotherapeutics in the second quarter valued at approximately $6,739,000. Nantahala Capital Management LLC acquired a new position in shares of Artiva Biotherapeutics during the second quarter worth $2,910,000. Finally, Alyeska Investment Group L.P. increased its position in shares of Artiva Biotherapeutics by 173.6% during the second quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock worth $2,654,000 after purchasing an additional 173,615 shares in the last quarter.

Artiva Biotherapeutics Price Performance

Artiva Biotherapeutics stock traded up $0.07 during trading hours on Friday, reaching $8.51. The stock had a trading volume of 25,345 shares, compared to its average volume of 374,650. The stock has a market cap of $415.86 million, a PE ratio of -2.59 and a beta of 2.18. Artiva Biotherapeutics has a 52 week low of $2.37 and a 52 week high of $14.53. The company has a fifty day simple moving average of $10.64 and a 200-day simple moving average of $9.10.

Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, hitting the consensus estimate of ($0.63). Research analysts predict that Artiva Biotherapeutics will post -2.62 earnings per share for the current fiscal year.

About Artiva Biotherapeutics

(Get Free Report)

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s platform is designed to produce off-the-shelf NK cell treatments that can be manufactured at scale and administered without requiring cells to be collected from each individual patient.

Artiva’s lead product candidate, AlloNK, also known as AB-101, is an investigational allogeneic NK cell therapy intended to target and eliminate antibody-coated cells.

See Also